The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...

A study found that prescriptions for GIP/GLP-1 RA drugs may reduce opioid overdose and alcohol intoxication rates in patients ...

Novo Nordisk says Massachusetts plays a key role in its bid to expand beyond its historic focus as a diabetes and obesity ...

Two companies — Eli Lilly and Novo Nordisk — dominate the weight-loss drug market and their stocks have surged in the recent ...

In a huge new statistical analysis, researchers have found more evidence than ever that drugs like Ozempic can help curb ...

Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...

We recently published an article titled, Jim Cramer’s Latest Lightning Round: 12 Stocks to Watch. In this article, we are ...

The case that Ozempic (NVO) and other GLP-1 medications could help people with substance use disorders is getting stronger.

Research published in the journal Addiction indicates that GLP-1 drugs like Ozempic may play a crucial role in reducing ...

Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.

Revolutionary weight management and diabetes medications could prove to be the next frontier in addiction recovery treatment medications.

The Beijing IP Court’s decision to revive a key semaglutide patent based on experimental data has far-reaching legal and ...